2.35
2.35 (0%)
As of Feb 14, 2025
Inhibikase Therapeutics, Inc. [IKT]
Source:
Company Overview
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary and other diseases including those that arise from aberrant signaling through the Abelson Tyrosine Kinase, and type III receptor tyrosine kinases including platelet derived growth factor receptors and proto-oncogene c-KIT ("c-KIT").
| Country | United States |
| Headquarters | atlanta, georgia |
| Phone Number | ( 678 ) 392-3419 |
| Industry | manufacturing |
| CEO | Milton H. Werner, Ph.D. |
| Website | inhibikase.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-28.6 |
| Net Income | $-27.5 |
| Net Cash | $47.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -48.7% |
| Profit as % of Stockholder Equity | -29% |
Management Effectiveness
| Return on Equity | -29% |
| Return on Assets | -27.9% |
| Turnover Ratio | |
| EBITA | $-28.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $98.6 |
| Total Liabilities | $3.7 |
| Operating Cash Flow | $-19.1 |
| Investing Cash Flow | $-37 |
| Financing Cash Flow | $103.5 |
